Alzinova AB (ALZ) - Total Liabilities

Latest as of September 2025: Skr9.05 Million SEK ≈ $973.60K USD

Based on the latest financial reports, Alzinova AB (ALZ) has total liabilities worth Skr9.05 Million SEK (≈ $973.60K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Alzinova AB cash conversion from operations to assess how effectively this company generates cash.

Alzinova AB - Total Liabilities Trend (2012–2024)

This chart illustrates how Alzinova AB's total liabilities have evolved over time, based on quarterly financial data. See Alzinova AB shareholders equity for net asset value and shareholders' equity analysis.

Alzinova AB Competitors by Total Liabilities

The table below lists competitors of Alzinova AB ranked by their total liabilities.

Company Country Total Liabilities
Olympio Metals Ltd
AU:OLY
Australia AU$810.12K
Indo Komoditi Korpora Tbk PT
JK:INCF
Indonesia Rp275.62 Billion
GreenPower Motor Company Inc
NASDAQ:GP
USA $40.31 Million
Jain Irrigation Systems Limited
NSE:JISLDVREQS
India Rs59.86 Billion
CPPGroup Plc
F:4CV1
Germany €22.06 Million
Corus Entertainment Inc
TO:CJR-B
Canada CA$2.04 Billion
OLB Group Inc
NASDAQ:OLB
USA $6.99 Million
Funding Circle Holdings PLC
LSE:FCH
UK GBX307.50 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Alzinova AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Alzinova AB.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Alzinova AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Alzinova AB (2012–2024)

The table below shows the annual total liabilities of Alzinova AB from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 Skr9.40 Million
≈ $1.01 Million
+0.77%
2023-12-31 Skr9.33 Million
≈ $1.00 Million
+53.27%
2022-12-31 Skr6.09 Million
≈ $655.15K
+89.09%
2021-12-31 Skr3.22 Million
≈ $346.48K
-32.81%
2020-12-31 Skr4.79 Million
≈ $515.68K
+8.40%
2019-12-31 Skr4.42 Million
≈ $475.71K
+89.33%
2018-12-31 Skr2.33 Million
≈ $251.26K
+0.26%
2017-12-31 Skr2.33 Million
≈ $250.60K
+64.85%
2016-12-31 Skr1.41 Million
≈ $152.02K
-9.79%
2015-12-31 Skr1.57 Million
≈ $168.51K
+165.74%
2014-12-31 Skr589.25K
≈ $63.41K
-19.06%
2013-12-31 Skr728.02K
≈ $78.35K
+328.80%
2012-12-31 Skr169.78K
≈ $18.27K
--

About Alzinova AB

ST:ALZ Sweden Biotechnology
Market Cap
$4.97 Million
Skr46.16 Million SEK
Market Cap Rank
#28380 Global
#642 in Sweden
Share Price
Skr0.44
Change (1 day)
-1.67%
52-Week Range
Skr0.44 - Skr2.18
All Time High
Skr26.90
About

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more